DNA 시퀀싱 시장 규모, 점유율 및 동향 분석 보고서 : 제품 및 서비스별, 기술별, 워크플로우별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

DNA Sequencing Market Growth & Trends:

The global DNA sequencing market size is expected to reach USD 48.22 billion by 2030, expanding at a CAGR of 21.65% from 2024 to 2030, according to a new report by Grand View Research, Inc. The incorporation of Artificial Intelligence (AI) has increased the utility of genomic data in clinical practices and thus creates a new frontier in the advancement of genomic data analysis. In May 2020, Nvidia Corporation developed new AI tools, genomic sequencing software, and speech recognition technologies to aid the COVID-19 research efforts. Thus, AI accelerates the variant annotation and prioritization in the clinical diagnosis, which drives the market.

Since the completion of the Human Genome Project, the DNA sequencing cost has declined precipitously. The cost of decoding one person's genome was around USD 50,000 a decade ago and currently has reached nearly USD 600 in the largest genomic centers. Recently, in February 2020, BGI claimed to reduce the cost to sequence the genome to USD 100. This is expected to expand the use of this technology for prenatal tests, cancer screening, and research studies.

With a significant decrease in cost coupled with the availability of funding, several start-ups have entered the market. For instance, in January 2020, Omniome, a startup firm from the U.S., raised USD 60.0 million in Series C financing to speed up the late-stage product development and product launch of its genetic sequencing platform, which consequently fuels market progression.

DNA Sequencing Market Report Highlights:

• Rise in the availability of services at affordable prices along with consulting services, training courses, and customer support are anticipated to drive the services segment at the fastest growth rate over the forecast period
• Constant technological advancements in third-generation techniques with the launch of new systems are expected to drive this segment at a lucrative CAGR
• For instance, in July 2019, Oxford Nanopore launched GridION Mk1, a benchtop, flexible NGS, data analysis device that improves the performance of the company's GridION X5 system
• On the basis of workflow, the data analysis step is anticipated to register a considerable CAGR throughout the forecast period
• The advent of workflow management systems with HTS-flow retrieves data from laboratory management systems and manages data analysis through a simple graphical user interface, subsequently streamlining the data analysis workflow
• These technologies are widely accepted in the oncology field to sequence and catalog gene mutations for the development of cancer diagnostic and therapeutics
• A rise in cancer cases globally is driving demand for oncology. It is estimated that there would be nearly 1.8 million new cancer cases in 2020 in the U.S.
• The clinical research segment is projected to witness the fastest growth rate over the forecast period, followed by hospitals and clinics
• Efforts undertaken by companies and government agencies to broaden the accessibility for NGS-based diagnostic tests in the hospitals and diagnostic centers for COVID-19 diagnosis is anticipated to drive the hospitals and clinics segment at a lucrative pace
• In Asia Pacific, the market is expected to progress with the highest CAGR over the forecast period owing to numerous research programs that involve the usage of these tools
• For instance, in October 2019, researchers from the Agency for Science, Technology and Research's Genome Institute of Singapore created the largest genetic databank of Asian populations to support the diagnosis of rare diseases

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product & Service
  • 1.2.2. Technology
  • 1.2.3. Workflow
  • 1.2.4. Application
  • 1.2.5. End-use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. DNA Sequencing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements in sequencing techniques
    • 3.2.1.2. Rising interest in genomics research and personalized medicine
    • 3.2.1.3. Increasing applications of DNA sequencing in clinical diagnostics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Data storage and management challenges
    • 3.2.2.2. Ethical and privacy concerns related to the use of sequencing technologies.
• 3.3. DNA Sequencing Market Analysis Tools
  • 3.3.1. Industry analysis - Porter's
  • 3.3.2. PESTEL analysis
  • 3.3.3. COVID-19 impact analysis

Chapter 4. DNA Sequencing Market: Product & Service Estimates & Trend Analysis

• 4.1. Product & Service Market Share, 2023 & 2030
• 4.2. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
  • 4.2.1. Consumables
    • 4.2.1.1. Consumables market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.2.2. Instruments
    • 4.2.2.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.2.3. Services
    • 4.2.3.1. Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. DNA Sequencing Market: Technology Estimates & Trend Analysis

• 5.1. Technology Market Share, 2023 & 2030
• 5.2. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following
  • 5.2.1. Sanger sequencing
    • 5.2.1.1. Sanger sequencing market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.2.2. Next-generation sequencing (NGS)
    • 5.2.2.1. Next-generation sequencing (NGS) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.2.2. Whole genome sequencing (WGS)
    • 5.2.2.2.1. Whole genome sequencing (WGS) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.2.3. Whole exome sequencing (WES)
    • 5.2.2.3.1. Whole exome sequencing (WES) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.2.4. Targeted sequencing & resequencing
    • 5.2.2.4.1. Targeted sequencing & resequencing market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.2.3. Third generation dna sequencing
    • 5.2.3.1. Third generation dna sequencing market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.3.2. Single-molecule real-time sequencing (SMRT)
    • 5.2.3.2.1. Single-molecule real-time sequencing (SMRT) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.2.3.3. Nanopore sequencing
    • 5.2.3.3.1. Nanopore sequencing market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. DNA Sequencing Market: Workflow Estimates & Trend Analysis

• 6.1. Workflow Market Share, 2023 & 2030
• 6.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.2.1. Pre-sequencing
    • 6.2.1.1. Pre-sequencing market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.2.2. Sequencing
    • 6.2.2.1. Sequencing Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.2.3. Data Analysis
    • 6.2.3.1. Data analysis Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. DNA Sequencing Market: Application Estimates & Trend Analysis

• 7.1. Application Market Share, 2023 & 2030
• 7.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.2.1. Oncology
    • 7.2.1.1. Oncology Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.2.2. Reproductive Health
    • 7.2.2.1. Reproductive health market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.2.3. Clinical Investigation
    • 7.2.3.1. Clinical investigation Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.2.4. Agrigenomics & Forensics
    • 7.2.4.1. Agrigenomics & forensics market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.2.5. HLA Typing/Immune System Monitoring
    • 7.2.5.1. HLA Typing/Immune System Monitoring market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.2.6. Metagenomics, Epidemiology, & Drug Development
    • 7.2.6.1. Metagenomics, epidemiology, & drug development market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.2.7. Consumer Genomics
    • 7.2.7.1. Consumer genomics market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.2.8. Others
    • 7.2.8.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. DNA Sequencing Market: End-use Estimates & Trend Analysis

• 8.1. End-use Market Share, 2023 & 2030
• 8.2. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.2.1. Academic Research
    • 8.2.1.1. Academic research market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.2.2. Clinical Research
    • 8.2.2.1. Clinical research market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.2.3. Hospitals & Clinics
    • 8.2.3.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.2.4. Pharmaceutical & Biotechnology Companies
    • 8.2.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.2.5. Others
    • 8.2.5.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. DNA Sequencing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2023 & 2030
• 9.2. North America
  • 9.2.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key country dynamics
    • 9.2.2.2. Regulatory framework
    • 9.2.2.3. Target disease prevalence
    • 9.2.2.4. Competitive scenario
    • 9.2.2.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.2.3. Canada
    • 9.2.3.1. Key country dynamics
    • 9.2.3.2. Regulatory framework
    • 9.2.3.3. Target disease prevalence
    • 9.2.3.4. Competitive scenario
    • 9.2.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 9.3. Europe
  • 9.3.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Target disease prevalence
    • 9.3.2.4. Competitive scenario
    • 9.3.2.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.3. Germany
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework
    • 9.3.3.3. Target disease prevalence
    • 9.3.3.4. Competitive scenario
    • 9.3.3.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.4. France
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. Regulatory framework
    • 9.3.4.3. Target disease prevalence
    • 9.3.4.4. Competitive scenario
    • 9.3.4.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.5. Italy
    • 9.3.5.1. Key country dynamics
    • 9.3.5.2. Regulatory framework
    • 9.3.5.3. Target disease prevalence
    • 9.3.5.4. Competitive scenario
    • 9.3.5.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.6. Spain
    • 9.3.6.1. Key country dynamics
    • 9.3.6.2. Regulatory framework
    • 9.3.6.3. Target disease prevalence k
    • 9.3.6.4. Competitive scenario
    • 9.3.6.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.7. Norway
    • 9.3.7.1. Key country dynamics
    • 9.3.7.2. Regulatory framework
    • 9.3.7.3. Target disease prevalence
    • 9.3.7.4. Competitive scenario
    • 9.3.7.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.8. Sweden
    • 9.3.8.1. Key country dynamics
    • 9.3.8.2. Regulatory framework
    • 9.3.8.3. Target disease prevalence
    • 9.3.8.4. Competitive scenario
    • 9.3.8.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.9. Denmark
    • 9.3.9.1. Key country dynamics
    • 9.3.9.2. Regulatory framework
    • 9.3.9.3. Target disease prevalence
    • 9.3.9.4. Competitive scenario
    • 9.3.9.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Target disease prevalence
    • 9.4.2.4. Competitive scenario
    • 9.4.2.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.3. China
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Target disease prevalence
    • 9.4.3.4. Competitive scenario
    • 9.4.3.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.4. India
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Target disease prevalence
    • 9.4.4.4. Competitive scenario
    • 9.4.4.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.5. Australia
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Target disease prevalence
    • 9.4.5.4. Competitive scenario
    • 9.4.5.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.6. South Korea
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Target disease prevalence
    • 9.4.6.4. Competitive scenario
    • 9.4.6.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.7. Thailand
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Target disease prevalence
    • 9.4.7.4. Competitive scenario
    • 9.4.7.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.5. Latin America
  • 9.5.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Target disease prevalence
    • 9.5.2.4. Competitive scenario
    • 9.5.2.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. Mexico
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Target disease prevalence
    • 9.5.3.4. Competitive scenario
    • 9.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. Argentina
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Target disease prevalence
    • 9.5.4.4. Competitive scenario
    • 9.5.4.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. MEA
  • 9.6.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Target disease prevalence
    • 9.6.2.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Target disease prevalence
    • 9.6.3.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. UAE
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework
    • 9.6.4.3. Target disease prevalence
    • 9.6.4.4. Competitive scenario
    • 9.6.4.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. Kuwait
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Target disease prevalence
    • 9.6.5.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2023
• 10.4. Company Profiles/Listing
  • 10.4.1. Thermo Fisher Scientific, Inc
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product & service benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. Agilent Technology
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product & service benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. Illumina, Inc.
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product & service benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. QIAGEN
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product & service benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. F. Hoffmann-La Roche Ltd.
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product & service benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. Oxford Nanopore Technologies plc.
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product & service benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. Macrogen, Inc.
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product & service benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. PerkinElmer Genomics
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product & service benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. PacBio
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product & service benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. BGI
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product & service benchmarking
    • 10.4.10.4. Strategic initiatives
  • 10.4.11. Bio-Rad Laboratories, Inc.
    • 10.4.11.1. Company overview
    • 10.4.11.2. Financial performance
    • 10.4.11.3. Product & service benchmarking
    • 10.4.11.4. Strategic initiatives
  • 10.4.12. Myriad Genetics
    • 10.4.12.1. Company overview
    • 10.4.12.2. Financial performance
    • 10.4.12.3. Product & service benchmarking
    • 10.4.12.4. Strategic initiatives
  • 10.4.13. PierianDx
    • 10.4.13.1. Company overview
    • 10.4.13.2. Financial performance
    • 10.4.13.3. Product & service benchmarking
    • 10.4.13.4. Strategic initiatives
  • 10.4.14. Partek Incorporated
    • 10.4.14.1. Company overview
    • 10.4.14.2. Financial performance
    • 10.4.14.3. Product & service benchmarking
    • 10.4.14.4. Strategic initiatives
  • 10.4.15. Eurofins Scientific
    • 10.4.15.1. Company overview
    • 10.4.15.2. Financial performance
    • 10.4.15.3. Product & service benchmarking
    • 10.4.15.4. Strategic initiatives